Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases

American Journal of Surgical Pathology

Volumn 37, Issue 3, 2013, Pages 399-405

  Graham, Rondell P ^a   Shrestha, Bijayee ^a   Caron, Bolette L ^a   Smyrk, Thomas C ^a   Grogg, Karen L ^a   Lloyd, Ricardo V ^a   Zhang, Lizhi ^a  

^a MAYO CLINIC   (United States)

Author keywords

Islet 1; metastases of unknown primary; neuroendocrine markers; neuroendocrine neoplasms; pancreas

Indexed keywords

INSULIN GENE ENHANCER BINDING PROTEIN ISL 1; INSULIN GENE ENHANCER BINDING PROTEIN ISL-1; LIM HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; CARCINOMA; HUMAN; METABOLISM; METASTASIS; PANCREAS TUMOR; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

CARCINOMA, NEUROENDOCRINE; HUMANS; LIM-HOMEODOMAIN PROTEINS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873985762     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826f042c     Document Type: Article

References (24)

1. Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine neoplasms of unknown primary sites. Endocr Pathol. 2004;15:247-252.
2. Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. 2005;123:394-404.
3. Modlin IM, Lye KD, Kidd MA. 5-decade analysis of 13,715 carcinoid neoplasms. Cancer. 2003;97:934-959.
4. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid neoplasms. Cancer. 1997;79:813-829.
5. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine neoplasms: consensus report of the National Cancer Institute Neuroendocrine Neoplasm clinical trials planning meeting. J Clin Oncol. 2011;29: 934-943.
6. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine neoplasms: its role as a marker of intestinal neuroendocrine neoplasms. Am J Surg Pathol. 2004;28:1169-1176.
7. Du EZ, Goldstraw P, Zacharias J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol. 2004;35:825-831.
8. Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine neoplasms: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009;33:1562-1569.
9. Schmitt AM, Riniker F, Anlauf M, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine neoplasms and their metastases. Am J Surg Pathol. 2008;32:420-425.
10. Koo J, Mertens RB, Mirocha JM, et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine neoplasms of pancreatic origin. Mod Pathol. 2012;25:893-902.
11. Jensen J. Gene regulatory factors in pancreatic development. Dev Dyn. 2004;229:176-200.
12. Ahlgren U, Pfaff SL, Jessell TM, et al. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 1997;385:257-260.
13. Karlsson O, Thor S, Norberg T, et al. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo-and a Cys-His domain. Nature. 1990;344: 879-882.
14. Dong J, Asa SL, Drucker DJ. Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. Mol Endocrinol. 1991;5:1633-1641.
15. Mutoh H, Hakamata Y, Sato K, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002;294:470-479.
16. Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology. 2002;122:689-696.
17. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17: 1392-1399.
18. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian neoplasms from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19-25.
19. Saad RS, Silverman JF, Khalifa MA, et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2009;17:196-201. Erratum in: Appl Immunohistochem Mol Morphol. 2009;17(5):464.
20. Long KB, Srivastava A, Hirsch MS, et al. PAX8 Expression in welldifferentiated pancreatic endocrine neoplasms: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid neoplasms. Am J Surg Pathol. 2010;34: 723-729.
21. Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine neoplasms from ileal and pulmonary well-differentiated neuroendocrine neoplasms and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412-424.
22. Lorenzo PI, Jimenez Moreno CM, Delgado I, et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine neoplasms. Histochem Cell Biol. 2011;136:595-607.
23. Cai YC, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine neoplasms. Hum Pathol. 2001;32:1087-1093.
24. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine neoplasms. Mod Pathol. 1999;12:5-8.